Clinical effect of pioglitazone hydrochloride combined with glimepiride treating obese type 2 diabetic patients

Wang Le; Zhao Wenting

doi:10.3760/cma.j.issn.1673-4777.2016.11.016

Abstract：Objective To observe the clinical effect of pioglitazone hydrochloride combined with glimepiride treating obese type 2 diabetic patients.Methods Totally 54 patients with obese type 2 diabetes from June 2013 to December 2014 in the 2nd Affiliated Hospital of Harbin Medical University were randomly divided into pioglitazone group,glimepiride group and pioglitazone combined with glimepiride group,with 18 cases in each group.The pioglitazone group had pioglitazone hydrochloride tablets 15-30 mg/time,1 time/d,orally administered before breakfast,the drug dosage could be adjusted depends on blood glucose values;the glimepiride group had glimepiride tablets 2 mg/time,1 time/d,orally administered 30 min before breakfast,the dosage could increase to 8 mg/d;the pioglitazone combined with glimepiride group orally took pioglitazone hydrochloride tablets 15-30 mg and glimepiride tablets 1 mg with a 0.5 h interval before breakfast,the glimepiride dosage was maintained and the pioglitazone dosage could be adjusted.After 12 weeks of treatment,fasting blood glucose,postprandial 2 h blood glucose,glycosylated hemoglobin and body mass index were analyzed and complications and adverse drug reactions were observed.Results Fasting blood glucose,postprandial 2 h blood glucose,glycosylated hemoglobin and body mass index in pioglitazone combined with glimepiride group were significantly lower than those in pioglitazone group andglimepiride group[(5.70 ± 0.31) mmol/L vs (9.00 ± 1.22),(10.50 ± 1.48) mmol/L;(7.00 ± 0.12) mmol/L vs (12.80 ± 0.44),(13.80 ± 0.12) mmol/L;(6.50 ± 0.03) ％ vs (11.00 ± 1.93) ％,(10.03 ± 1.00) ％;(19.50 ± 0.55) kg/m2 vs (24.30 ± 0.78),(22.00 ± 0.65) kg/m2] (all P ＜ 0.05).There were no acute complications and adverse drug reactions in 3 groups.Conclusion Pioglitazone hydrochloride combined with glimepiride is more effective compared to single use of pioglitazone or glimepiride in the treatment of obese type 2 diabetes.